| Features: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| α-Bisabolol — α-Bisabolol is a naturally occurring monocyclic sesquiterpene alcohol best known as a major bioactive constituent of chamomile essential oil, especially German chamomile (Matricaria chamomilla / Matricaria recutita) and related chamomile preparations. It is a small lipophilic phytochemical classified as a plant-derived essential-oil terpene alcohol, with common abbreviations including α-BSB, BSB, and levomenol for the (-)-α-bisabolol enantiomer. In oncology research it is mainly a preclinical pro-apoptotic and anti-invasive compound with preferential mitochondrial stress effects in cancer models; in clinical deployment it remains a cosmetic/natural-health constituent rather than an approved anticancer drug. -The main components in German chamomile are terpenoid; α-bisabolol and its oxide azulenes, such as chamazulene (1–15%); and apigenin. Roman chamomile, on the other hand, contains mainly angelic acid and tiglic acid esters. Apigenin is a main bioactive component and considered a quality marker of chamomile.Primary mechanisms (ranked):
Bioavailability / PK relevance: α-Bisabolol is highly lipophilic and poorly water soluble, so systemic translation depends strongly on formulation, route, dose, and vehicle. Essential-oil or neat-compound exposure does not imply predictable plasma exposure, and advanced delivery systems such as cyclodextrin complexes, nanoemulsions, or lipid carriers may be required for reproducible systemic or CNS delivery. In-vitro vs systemic exposure relevance: Most anticancer findings use direct in-vitro exposure at micromolar to high-micromolar concentrations, often with solvent-assisted delivery. These concentrations may exceed achievable free systemic exposure after ordinary chamomile tea, dietary chamomile, or topical/cosmetic use. Chamomile oil composition is also chemotype-dependent, so α-bisabolol content can vary substantially. Clinical evidence status: Cancer evidence is preclinical only. There are human trials of α-bisabolol-containing topical products for non-cancer indications, and chamomile has natural-health/traditional-use monographs for digestive, inflammatory gastrointestinal, and calmative uses, but there is no established human oncology indication, no approved anticancer label, and no cancer RCT evidence for α-bisabolol or chamomile oil. Mechanistic Profile
TSF legend: P: 0–30 min; R: 30 min–3 hr; G: >3 hr Alzheimer’s disease relevance: α-Bisabolol has meaningful preclinical AD relevance through amyloid-β toxicity reduction, mitochondrial protection, anti-inflammatory activity, oxidative-stress reduction, and possible cholinesterase-related effects. Evidence includes Aβ-induced cell and animal/C. elegans models, scopolamine-memory models for α-bisabolol derivatives, and chamomile essential-oil studies with α-bisabolol-rich composition. However, there is no established human AD clinical evidence for α-bisabolol, and brain exposure is likely formulation-dependent because the compound is lipophilic and poorly water soluble. |
| Source: |
| Type: |
| AChE is an enzyme that rapidly hydrolyzes the neurotransmitter acetylcholine into choline and acetate, terminating cholinergic signals. - In some cancers, studies have reported reduced AChE activity, which may contribute to an accumulation of acetylcholine. - Lower levels or loss of AChE expression/activity have been associated with more aggressive tumor behavior and poor prognosis, possibly due to unchecked cholinergic signaling. For AD (Alzheimer's), AChE inhibitors are used, to allow ACh, and ChAT to increase along with acetyl-CoA -Natural AChE inhibitors: Ferulic Acid, Caffeic Acid, Rosmarinic Acid, Sage -AChE inhibitors only temporarily relieve some of the disease’s cognitive symptoms and do not stop the patient’s cognitive loss -adverse effects such as disorientation, falls, dizziness, and fatigue may occur with these medications and should be used only as recommended - Natural AChE inhibitors paper |
| 6551- | BSB, | α-bisabolol β-d-fucopyranoside (ABFP) ameliorates scopolamine-induced memory deficits through cholinesterase inhibition and attenuation of oxidative stress in zebrafish (Danio rerio) |
| - | in-vivo, | AD, | NA |
| 6552- | BSB, | Biochemical characterization of chamomile essential oil: Antioxidant, antibacterial, anticancer and neuroprotective activity and potential treatment for Alzheimer's disease |
| - | in-vivo, | AD, | NA |
| 6542- | BSB, | Health Benefits, Pharmacological Effects, Molecular Mechanisms, and Therapeutic Potential of α-Bisabolol |
| - | Review, | Var, | NA | - | Review, | Park, | NA | - | Review, | AD, | NA |
| 6550- | BSB, | α-bisabolol β-D-fucopyranoside as a potential modulator of β-amyloid peptide induced neurotoxicity: An in vitro &in silico study |
| - | in-vivo, | AD, | NA |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:413 Target#:1329 State#:% Dir#:%
wNotes=0 sortOrder:rid,rpid